{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:15:41Z","timestamp":1784139341459,"version":"3.55.0"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,7,17]],"date-time":"2006-07-17T00:00:00Z","timestamp":1153094400000},"content-version":"vor","delay-in-days":197,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction and Objectives<\/jats:title><jats:p>The dosage of the antimuscarinic drugs: Tolterodine ER or Trospium was increased to a higher\u2010than\u2010recommended dosage in patients where the manufacturer's recommended dosage had failed. All patients were suffering from neurogenic detrusor overactivity incontinence. Tolerability and success were evaluated in the present study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Twenty\u2010one patients with neurogenic detrusor overactivity were evaluated: 17 with spinal cord injury, 3 with multiple sclerosis, and 1 with a meningomyelocele. All patients catheterized themselves or were catheterized. If neurogenic detrusor overactivity continued and the medication was well tolerated, the dosage was doubled to either 8 mg of Tolterodine ER [2\u2009\u00d7\u20094 mg (n\u2009=\u200911)] or 90 mg of Trospium [3\u2009\u00d7\u200930 mg (n\u2009=\u200910)]. The follow\u2010up was monitored by a bladder diary and urodynamic evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixteen patients significantly decreased their incontinence episodes from 8\u201312 episodes before to 0\u20132 episodes during the doubled treatment. The reflex volume increased from 202\u2009\u00b1\u200968 to 332\u2009\u00b1\u200950 ml (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Cystometric capacity enlarged from 290\u2009\u00b1\u200956 to 453\u2009\u00b1\u200963 ml (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). One patient had to stop the medication because of intolerable side effects and five patients did not experience satisfactory benefit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The increased dosage of Tolterodine or Trospium is an effective treatment in patients with neurogenic bladder. Neurourol. Urodynam. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.20289","type":"journal-article","created":{"date-parts":[[2006,7,17]],"date-time":"2006-07-17T23:55:39Z","timestamp":1153180539000},"page":"441-445","source":"Crossref","is-referenced-by-count":83,"title":["Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage"],"prefix":"10.1002","volume":"25","author":[{"given":"M.","family":"Horstmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stenzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.D.","family":"Sievert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,17]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"439","article-title":"Tropium chloride in patients with motor urge syndrome (detrusor instability): A double\u2010blind, randomised, multi\u2010center, placebo\u2010controlled study","volume":"1","author":"Alloussi S","year":"1998","journal-title":"J Clin Res"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042307-200211000-00005"},{"key":"e_1_2_1_4_1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/10790268.2004.11753751","article-title":"Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity","volume":"27","author":"Ethans KD","year":"1995","journal-title":"J Spinal Cord Med"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.4.267.30943"},{"key":"e_1_2_1_6_1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","article-title":"Controlled, double\u2010blind, multicentre clinical trial to investigate long\u2010term tolerability and efficacy of trospium chloride in patients with detrusor instability","volume":"20","author":"Halaska M","year":"2003","journal-title":"World J Urol"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00177-X"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1995.tb07264.x"},{"key":"e_1_2_1_9_1","unstructured":"MadersbacherH MenariniM D\u00f6rsamJ et al.2004.Anticholinergic therapy of neurogenic detrusor overactivity: Evaluation of an oral trospium chloride (TC) dose adjustment. Abstract DGU."},{"key":"e_1_2_1_10_1","first-page":"53","article-title":"Trospiumchlorid versus oxybutinin in der Behandlung der hyperaktiven Blas\u0300\u2014eine randomisierte, doppelblinde Studie","volume":"13","author":"Osca\u2010Garcia JM","year":"1997","journal-title":"Jatros Uro"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000282207"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05343.x"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010528"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<499::AID-NAU6>3.0.CO;2-8"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01113-4"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.20289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T02:21:55Z","timestamp":1700533315000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.20289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["10.1002\/nau.20289"],"URL":"https:\/\/doi.org\/10.1002\/nau.20289","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}